ArticleBMJ open2025

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.

Timothy Price et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.